GSE133933 fibulin-3 knockdown 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE133933_fibulin-3 knockdown_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE133933_fibulin-3 knockdown_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE133933_fibulin-3 knockdown_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE133933_fibulin-3 knockdown_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 1152

Gene

OFD1 pseudogene 1 Y-linked

Gene

ribosomal protein L21 pseudogene 4

Gene

ribosomal protein L6

Gene

transmembrane 4 L six family member 19

Gene

transcription factor binding to IGHM enhancer 3

Gene

ribosomal protein S20

Gene

synoviolin 1

Gene

protein tyrosine phosphatase receptor type N

Gene

Myb/SANT DNA binding domain containing 3

  • Gene

    long intergenic non-protein coding RNA 1152


  • Gene

    OFD1 pseudogene 1 Y-linked


  • Gene

    ribosomal protein L21 pseudogene 4


  • Gene

    ribosomal protein L6


  • Gene

    transmembrane 4 L six family member 19


  • Gene

    transcription factor binding to IGHM enhancer 3


  • Gene

    ribosomal protein S20



  • Gene

    protein tyrosine phosphatase receptor type N


  • Gene

    Myb/SANT DNA binding domain containing 3

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.